Nucleic Acid Synthesizer Market Size, Share, Growth, and Industry Analysis, By Type (Laboratory Scale, Industrial Scale, Large Scale), By Application (Biotechnology Companies, Academic and Research Organizations, Contract Research Organizations (CRO)), Regional Insights and Forecast to 2035

Nucleic Acid Synthesizer Market Overview

The global Nucleic Acid Synthesizer Market size estimated at USD 1118.94 million in 2026 and is projected to reach USD 1995.02 million by 2035, growing at a CAGR of 6.64% from 2026 to 2035.

The Nucleic Acid Synthesizer Market is witnessing significant expansion due to increasing demand for synthetic DNA and RNA products across biotechnology, pharmaceutical, and genomic research sectors. More than 68% of oligonucleotide manufacturing facilities adopted automated nucleic acid synthesizers in 2025 for high-throughput production efficiency. Over 52,000 synthetic oligonucleotide batches were processed globally during 2024 for diagnostics and therapeutic applications. Laboratory automation penetration reached 61% in advanced genomic facilities, while RNA-based therapeutic programs exceeded 3,200 active projects worldwide. Continuous advancements in phosphoramidite chemistry improved synthesis accuracy to 99.4%, supporting rapid deployment of personalized medicine, CRISPR gene editing, and mRNA vaccine development programs.

The United States accounted for 39% of global nucleic acid synthesizer installations in 2025 due to extensive genomic sequencing activities and biopharmaceutical manufacturing capabilities. More than 1,450 biotechnology laboratories in the country integrated automated DNA synthesizers for research and clinical workflows. The U.S. government allocated over 18% higher federal genomic research funding during 2024 compared to 2022, accelerating demand for RNA synthesis equipment. Approximately 72% of pharmaceutical companies engaged in nucleic acid therapeutic research adopted laboratory-scale synthesizers. Over 620 academic institutes in the United States conducted synthetic biology programs requiring oligonucleotide synthesis systems for CRISPR, antisense oligonucleotide, and mRNA research applications.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 64% of biotechnology laboratories increased adoption of automated nucleic acid synthesizers, while synthetic RNA demand expanded by 58% due to rising mRNA therapeutic and vaccine development activities globally.
• Major Market Restraint: Approximately 47% of small research facilities reported high operational and maintenance costs, while 41% experienced workflow delays caused by expensive reagents and skilled labor shortages.
• Emerging Trends: Around 62% of manufacturers introduced AI-enabled synthesis automation systems, while demand for high-throughput oligonucleotide synthesis platforms increased by 56% across pharmaceutical development facilities.
• Regional Leadership: North America held nearly 38% market share in 2025, supported by 71% higher genomic research infrastructure adoption and 66% participation in synthetic biology innovation programs.
• Competitive Landscape: The top five manufacturers controlled approximately 59% of total global installations, while automated large-scale synthesis systems represented 54% of newly deployed platforms during 2025.
• Market Segmentation: Industrial-scale synthesizers accounted for nearly 43% market share, while biotechnology companies contributed 48% of overall application demand due to expanding nucleic acid therapeutic production.
• Recent Development: More than 51% of newly launched synthesizer systems integrated cloud-based monitoring and automated purification technologies, improving synthesis efficiency by 37% in commercial laboratories.

Nucleic Acid Synthesizer Market Latest Trends

The Nucleic Acid Synthesizer Market is evolving rapidly with increasing implementation of automated synthesis technologies and precision genomic manufacturing systems. More than 67% of pharmaceutical companies engaged in nucleic acid therapeutic development adopted advanced DNA and RNA synthesizers during 2025. Automated phosphoramidite synthesis platforms reduced synthesis cycle times by 33%, while error rates declined by 24% through integration of AI-supported quality monitoring systems. Demand for RNA synthesis systems increased by 59% due to growth in mRNA vaccine pipelines and antisense oligonucleotide therapies.

High-throughput synthesis emerged as a major trend, with approximately 46% of research laboratories upgrading to multi-channel synthesizer platforms capable of producing over 3,000 oligonucleotides weekly. Compact laboratory-scale systems experienced 41% installation growth across academic and clinical research institutions. Cloud-enabled instrument monitoring systems improved operational efficiency by 36% and reduced downtime by 28% in commercial synthesis facilities. Sustainable synthesis processes also gained traction, with 39% of manufacturers introducing solvent-reduction technologies and recyclable reagent systems. Custom nucleic acid synthesis demand increased by 53% due to personalized medicine applications and CRISPR-based gene editing research. Furthermore, over 44% of newly developed synthesizers incorporated integrated purification modules, improving product purity levels above 99%. Asia-Pacific manufacturing facilities expanded synthetic oligonucleotide production capacity by 48%, supporting increasing global demand for diagnostic probes, therapeutic nucleic acids, and synthetic biology applications.

Nucleic Acid Synthesizer Market Dynamics

DRIVER

" Rising demand for genomic medicine and synthetic biology applications."

The increasing adoption of genomic medicine and synthetic biology technologies is significantly accelerating the Nucleic Acid Synthesizer Market. More than 74% of advanced pharmaceutical research programs integrated synthetic oligonucleotides into therapeutic development workflows during 2025. The number of active mRNA therapeutic projects exceeded 3,400 globally, while CRISPR gene-editing research activities increased by 49% compared to 2023. Automated nucleic acid synthesizers improved laboratory productivity by 42%, enabling rapid DNA and RNA sequence production for diagnostic and therapeutic applications. Approximately 68% of biotechnology firms expanded investments in synthetic biology infrastructure, while high-throughput synthesizer deployment increased by 44% across commercial manufacturing facilities. Demand for antisense oligonucleotides and siRNA therapies also expanded by 37%, further supporting equipment adoption across pharmaceutical and clinical laboratories.

RESTRAINT

" High operational complexity and expensive synthesis reagents."

The Nucleic Acid Synthesizer Market faces restraints due to elevated operational costs and technical complexities associated with synthesis workflows. Approximately 45% of small biotechnology laboratories reported difficulties managing reagent procurement and maintenance expenses. High-purity phosphoramidite reagents experienced 21% cost increases during 2024, impacting operational budgets for research organizations. More than 38% of facilities reported challenges associated with skilled technician shortages required for operating advanced automated synthesizers. Instrument calibration and purification procedures increased workflow processing times by 29% in medium-scale laboratories. Additionally, synthesis waste disposal compliance costs increased by 18% due to stricter laboratory environmental regulations. Around 31% of academic institutions delayed upgrading synthesis infrastructure because of limited funding availability and expensive instrument integration requirements.

OPPORTUNITY

" Expansion of personalized medicine and RNA therapeutics."

The rapid expansion of personalized medicine programs and RNA therapeutics presents substantial opportunities for the Nucleic Acid Synthesizer Market. More than 61% of precision medicine initiatives adopted customized nucleic acid synthesis workflows for targeted therapeutic development. RNA-based drug candidates increased by 52% globally during 2025, while clinical trials involving oligonucleotide therapies surpassed 1,900 studies worldwide. Automated RNA synthesizers improved sequence accuracy by 34%, supporting commercial-scale therapeutic manufacturing. Demand for personalized cancer treatment solutions increased by 46%, encouraging biotechnology companies to expand synthesis capacities. Approximately 57% of healthcare genomic research projects incorporated synthetic nucleic acid technologies for biomarker discovery and companion diagnostics. Emerging economies also demonstrated 43% growth in biotechnology infrastructure investment, creating additional opportunities for large-scale synthesis equipment manufacturers.

CHALLENGE

" Maintaining synthesis accuracy and scalability."

Maintaining consistent synthesis quality while scaling production remains a significant challenge within the Nucleic Acid Synthesizer Market. Approximately 36% of large-scale manufacturers reported sequence fidelity concerns during long-chain oligonucleotide synthesis processes. Error accumulation rates increased by 19% in sequences exceeding 200 nucleotides, requiring advanced purification and verification systems. More than 41% of facilities experienced workflow bottlenecks due to integration challenges between synthesizers and downstream purification platforms. Regulatory compliance requirements for therapeutic-grade nucleic acid manufacturing increased quality assurance workloads by 32%. Furthermore, approximately 28% of manufacturers faced delays in validating automated synthesis systems for clinical applications. Rapid technological evolution also created challenges related to continuous equipment upgrades and software compatibility management across research and commercial production environments.

Nucleic Acid Synthesizer Market Segmentation 

The Nucleic Acid Synthesizer Market is segmented by type and application based on production scale and end-user requirements. Industrial-scale synthesizers accounted for 43% market share due to increasing commercial oligonucleotide production activities. Laboratory-scale systems represented 34% share because of strong adoption across research institutes and academic laboratories. Biotechnology companies contributed nearly 48% of application demand, supported by rising therapeutic nucleic acid development projects. Academic and research organizations held 31% market share through genomic sequencing and synthetic biology research initiatives. Contract research organizations accounted for 21% share due to outsourcing trends in nucleic acid synthesis and analytical testing services.

Download Free Sample to learn more about this report.

By Type

Laboratory Scale: Laboratory-scale nucleic acid synthesizers accounted for approximately 34% of the market due to increasing utilization across universities, diagnostic centers, and genomic research laboratories. More than 4,200 academic laboratories globally operated compact automated synthesizers during 2025. These systems reduced synthesis turnaround times by 31% and improved sequence reproducibility by 27%. Small-scale synthesizers capable of producing 96 oligonucleotide sequences simultaneously experienced 38% installation growth across clinical research institutes. North America represented 41% of laboratory-scale deployments, while Asia-Pacific recorded 29% adoption growth. Approximately 58% of CRISPR-focused research facilities integrated laboratory-scale RNA synthesis systems for gene editing experiments and biomarker analysis applications.

Industrial Scale: Industrial-scale synthesizers represented nearly 43% market share owing to increasing commercial production of oligonucleotides for therapeutics and diagnostics. More than 760 industrial synthesis facilities globally expanded production capacities during 2025. Automated industrial platforms improved batch processing efficiency by 46% and reduced synthesis waste generation by 22%. Pharmaceutical manufacturing companies accounted for 57% of industrial-scale equipment demand. Europe held approximately 32% share in industrial synthesis installations due to advanced biopharmaceutical production infrastructure. Integrated purification and quality monitoring systems improved product purity levels above 99.2%, supporting regulatory compliance for therapeutic-grade nucleic acid manufacturing.

Large Scale: Large-scale nucleic acid synthesizers accounted for approximately 23% market share and are primarily utilized in high-volume commercial manufacturing operations. These systems processed over 12,000 oligonucleotide sequences monthly in major biotechnology production facilities. More than 49% of large-scale synthesis facilities supported mRNA vaccine and therapeutic RNA production during 2025. Automated reagent handling technologies reduced manual intervention by 63%, while advanced purification modules improved operational productivity by 39%. Asia-Pacific recorded 36% growth in large-scale synthesis infrastructure investments due to expanding biotechnology manufacturing hubs in China, Japan, and South Korea. Large-scale systems also supported increasing demand for DNA data storage and synthetic biology industrial applications.

By Application

Biotechnology Companies: Biotechnology companies dominated the Nucleic Acid Synthesizer Market with nearly 48% application share due to increasing therapeutic nucleic acid development activities. More than 2,700 biotechnology firms globally utilized automated synthesizers for RNA therapeutics, CRISPR editing, and antisense oligonucleotide production. High-throughput systems improved experimental throughput by 44% in drug discovery programs. Approximately 66% of mRNA therapeutic developers adopted industrial-scale synthesizers during 2025. North America accounted for 42% of biotechnology company demand, supported by advanced genomic research infrastructure and growing synthetic biology investment initiatives.

Academic and Research Organizations: Academic and research organizations represented approximately 31% market share due to rising genomic sequencing and synthetic biology research programs. More than 5,600 university laboratories globally utilized DNA synthesizers for molecular biology and genetic engineering applications. Research funding for nucleic acid technologies increased by 26% during 2025, supporting laboratory infrastructure expansion. Europe accounted for 35% of academic installations because of strong public biotechnology research programs. Approximately 54% of university-based genomic projects integrated automated oligonucleotide synthesis workflows for personalized medicine and biomarker research studies.

Contract Research Organizations (CRO): Contract research organizations held nearly 21% market share due to increasing outsourcing of nucleic acid synthesis and analytical testing services. More than 1,100 CRO facilities globally operated industrial and laboratory-scale synthesizers during 2025. Outsourced oligonucleotide manufacturing demand increased by 37% among pharmaceutical companies seeking cost optimization and accelerated development timelines. Asia-Pacific accounted for 33% of CRO market expansion because of growing clinical research outsourcing activities. Automated synthesis systems improved service turnaround times by 28%, while integrated purification technologies increased client satisfaction rates by 34% across commercial research organizations.

Nucleic Acid Synthesizer Market Regional Outlook

The Nucleic Acid Synthesizer Market demonstrates strong regional diversification supported by expanding biotechnology research, genomic medicine, and synthetic biology investments. North America accounted for 38% market share due to advanced pharmaceutical infrastructure and extensive therapeutic development activities. Europe held 29% share through strong genomic research programs and biopharmaceutical manufacturing expansion. Asia-Pacific represented 25% share driven by rapid biotechnology industrialization and government-backed genomic initiatives. Middle East & Africa accounted for 8% share, supported by improving healthcare research infrastructure and increasing molecular diagnostics adoption across regional laboratories and academic institutions.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominated the Nucleic Acid Synthesizer Market with approximately 38% market share during 2025 due to advanced biotechnology infrastructure and significant investments in genomic medicine. The United States accounted for nearly 84% of regional installations, supported by more than 1,450 biotechnology laboratories utilizing automated synthesis systems. Canada contributed 11% regional share through increasing synthetic biology research initiatives and government-supported genomic sequencing programs. More than 71% of pharmaceutical companies operating in North America integrated nucleic acid synthesizers for RNA therapeutic and oligonucleotide production workflows. The region recorded over 3,800 active genomic medicine research projects during 2025, while mRNA therapeutic development activities expanded by 46%. Automated high-throughput synthesis systems improved manufacturing efficiency by 43% across commercial facilities. Approximately 62% of large biotechnology companies upgraded to cloud-enabled synthesis monitoring systems.

EUROPE

Europe accounted for approximately 29% of the global Nucleic Acid Synthesizer Market due to strong pharmaceutical manufacturing capabilities and expanding genomic medicine programs. Germany, the United Kingdom, and France collectively represented 63% of regional market demand. More than 970 biotechnology and pharmaceutical laboratories across Europe adopted automated DNA and RNA synthesis systems during 2025. European pharmaceutical manufacturers increased investments in oligonucleotide therapeutics by 34%, while synthetic biology research projects exceeded 1,200 active programs. Industrial-scale synthesizers represented 47% of regional equipment installations due to growing therapeutic nucleic acid manufacturing activities. Approximately 58% of research institutes integrated automated purification systems to improve synthesis accuracy and regulatory compliance.

ASIA-PACIFIC

Asia-Pacific represented approximately 25% market share in the Nucleic Acid Synthesizer Market and demonstrated the fastest expansion in biotechnology infrastructure during 2025. China, Japan, South Korea, and India collectively accounted for 79% of regional installations. More than 690 biotechnology manufacturing facilities in Asia-Pacific integrated automated oligonucleotide synthesis systems during the year. Government-backed genomic research programs increased biotechnology infrastructure investments by 44% across the region. China alone accounted for 38% of Asia-Pacific demand due to large-scale expansion of synthetic biology and pharmaceutical manufacturing operations. Japan recorded 31% growth in RNA therapeutic research activities, while South Korea increased laboratory automation adoption by 36%.

MIDDLE EAST & AFRICA

The Middle East & Africa accounted for approximately 8% of the global Nucleic Acid Synthesizer Market due to increasing adoption of molecular diagnostics and biotechnology research programs. The United Arab Emirates, Saudi Arabia, and South Africa collectively represented 67% of regional market demand during 2025. More than 210 healthcare and academic laboratories across the region implemented automated nucleic acid synthesis systems. Government healthcare modernization initiatives increased genomic research investments by 28% across Middle Eastern countries. Approximately 46% of regional biotechnology laboratories adopted compact laboratory-scale synthesizers for diagnostic and educational applications. Academic research institutes accounted for 41% of regional demand due to expanding molecular biology and genetic research activities. Africa demonstrated increasing interest in genomic surveillance and infectious disease diagnostics, with molecular testing infrastructure expanding by 32% during 2025. More than 120 regional diagnostic laboratories incorporated synthetic oligonucleotide workflows for pathogen detection and sequencing applications. Industrial-scale adoption remained limited but increased by 19% due to growing pharmaceutical manufacturing capabilities.

List of Top Nucleic Acid Synthesizer Companies

• Thermo Fisher
• K&A
• Beckman (Danaher)
• GE Healthcare
• Polygen
• BioAutomation
• Biolytic Lab Performance
• Cytiva
• Kilobaser
• CSBio
• OligoMaker
• Inscinstech
• Tsingke Biotechnology
• DNA Chem
• Hunan Honya Biotech

List of Top 2 Companies Market Share

Thermo Fisher: Thermo Fisher accounted for approximately 18% of global nucleic acid synthesizer installations during 2025, supported by strong biotechnology partnerships, automated synthesis platforms, and widespread adoption across pharmaceutical manufacturing and genomic research laboratories.

Beckman (Danaher): Beckman (Danaher) held nearly 14% market share due to extensive deployment of laboratory automation systems, integrated purification technologies, and expanding demand from industrial oligonucleotide manufacturing facilities worldwide.

Investment Analysis and Opportunities

The Nucleic Acid Synthesizer Market continues attracting substantial investments due to increasing demand for genomic medicine, RNA therapeutics, and synthetic biology applications. Biotechnology infrastructure investments increased by 42% globally during 2025, while over 610 pharmaceutical companies expanded nucleic acid production capabilities. More than 47% of investment activities targeted industrial-scale synthesis automation and high-throughput oligonucleotide manufacturing technologies. North America accounted for 39% of total biotechnology equipment investment initiatives, supported by strong genomic research funding and advanced pharmaceutical manufacturing capabilities. Asia-Pacific experienced 44% growth in biotechnology infrastructure expansion, particularly in China, Japan, and South Korea. Approximately 36% of newly funded biotechnology startups focused on RNA therapeutics and CRISPR-based applications requiring advanced synthesis systems.

Automated cloud-connected synthesizers attracted significant investment due to operational efficiency improvements exceeding 34%. Investors also focused on environmentally optimized synthesis technologies, with 29% of newly launched manufacturing projects integrating solvent-reduction systems and recyclable reagent processes. Personalized medicine initiatives created additional opportunities, as precision genomic therapy programs increased by 51% worldwide. Contract research organizations expanded investments in outsourced oligonucleotide manufacturing facilities by 32% during 2025. Furthermore, strategic collaborations between pharmaceutical companies and synthesis equipment manufacturers increased by 27%, supporting rapid commercialization of therapeutic nucleic acid technologies and high-capacity synthesis platforms.

New Product Development

New product development activities in the Nucleic Acid Synthesizer Market accelerated significantly during 2025 as manufacturers introduced advanced automation, AI-supported monitoring, and integrated purification technologies. More than 53% of newly launched systems incorporated real-time synthesis tracking capabilities, improving sequence accuracy by 31%. Compact modular synthesizers capable of processing 192 oligonucleotide sequences simultaneously gained strong adoption across academic and biotechnology laboratories. RNA synthesis platforms represented 46% of total product launches due to increasing mRNA therapeutic and vaccine development demand. Manufacturers introduced automated reagent dispensing systems that reduced manual intervention by 61% and improved operational productivity by 37%. Approximately 42% of newly developed systems integrated cloud-based workflow management and predictive maintenance software.

Large-scale industrial synthesis platforms capable of continuous oligonucleotide manufacturing experienced 33% deployment growth across commercial biotechnology facilities. Sustainability-focused innovations also emerged, with 38% of product launches incorporating solvent-reduction technologies and energy-efficient purification systems. Hybrid synthesizers supporting both DNA and RNA synthesis applications improved laboratory flexibility by 28%. Manufacturers additionally focused on miniaturization and portability, with portable laboratory-scale synthesizers reducing equipment footprint by 24%. Advanced purification modules improved oligonucleotide purity levels above 99.3%, supporting therapeutic-grade manufacturing requirements. Multi-channel synthesis systems capable of parallel sequence production expanded by 41%, enabling higher throughput for genomic medicine and synthetic biology research applications.

Five Recent Developments (2023-2025)

• Thermo Fisher introduced a next-generation automated RNA synthesizer in 2024 capable of improving synthesis throughput by 36% while reducing reagent consumption by 19%.
• Beckman (Danaher) expanded laboratory automation integration in 2025, increasing oligonucleotide processing efficiency by 32% across industrial synthesis facilities.
• Cytiva launched an advanced purification-enabled synthesis platform during 2023 that improved nucleic acid purity levels to 99.4% for therapeutic manufacturing applications.
• BioAutomation developed a high-throughput multi-channel synthesizer in 2024 capable of processing over 3,200 oligonucleotide sequences weekly for commercial laboratories.
• Tsingke Biotechnology expanded large-scale oligonucleotide production infrastructure by 29% in 2025 to support increasing RNA therapeutic and synthetic biology demand.

Report Coverage of Nucleic Acid Synthesizer Market

The Nucleic Acid Synthesizer Market report provides comprehensive analysis of technological advancements, production capacity expansion, application trends, and regional industry performance. The report evaluates more than 15 major manufacturers and analyzes over 45 product categories associated with DNA and RNA synthesis systems. Approximately 68% of analyzed facilities implemented automated synthesis technologies during 2025, demonstrating increasing industry-wide laboratory automation adoption. The report covers segmentation by type, including laboratory-scale, industrial-scale, and large-scale synthesizers, while examining operational efficiency improvements, purification technologies, and synthesis throughput performance. More than 52% of market demand originated from biotechnology companies, while academic and research organizations contributed significant installation growth across genomic medicine programs.

Regional analysis within the report includes North America, Europe, Asia-Pacific, and Middle East & Africa, with detailed evaluation of biotechnology infrastructure investments, pharmaceutical manufacturing expansion, and genomic research activities. North America accounted for 38% market share, while Asia-Pacific demonstrated the fastest industrial expansion with 44% biotechnology investment growth. The report further analyzes market dynamics including drivers, restraints, opportunities, and challenges associated with nucleic acid synthesis workflows and therapeutic applications. More than 3,400 active RNA therapeutic development projects and 1,900 oligonucleotide clinical trials were evaluated within the research scope. Product innovation trends, automated synthesis technologies, AI-supported monitoring systems, and sustainability initiatives are also extensively covered throughout the market assessment.